Stephen A Sherwin has sold stock and made no open-market buys since Jun 2018

Stephen A. Sherwin, M.D. is a corporate insider and independent director at Neurocrine Biosciences, Inc., where he has served on the Board of Directors since 1999.( A medical oncologist by training, he currently divides his time between advisory work in the life sciences industry and patient care and teaching, serving as a Clinical Professor of Medicine at the University of California, San Francisco, and a volunteer Attending Physician in Hematology-Oncology at Zuckerberg San Francisco General Hospital.( In addition to his role at Neurocrine, Sherwin is a director of Biogen and Aduro Biotech and a venture partner at Third Rock Ventures.(

Over a biotechnology career spanning more than 35 years, Sherwin has held senior leadership roles including Chairman and Chief Executive Officer of Cell Genesys, Inc., and co‑founder and Chairman of Ceregene, Inc. and Abgenix, Inc., both of which were later acquired by larger biopharmaceutical companies.( Earlier in his career he worked at Genentech, Inc., rising to Vice President of Clinical Research, and he previously served on the staff of the National Cancer Institute.( Sherwin holds a B.A. in Biology from Yale University, where he graduated summa cum laude, and an M.D. from Harvard Medical School, and he is board‑certified in internal medicine and medical oncology.( His recent Form 4 filing for Neurocrine Biosciences reports the grant of restricted stock units in his capacity as a director, reflecting his ongoing status as a corporate insider of NBIX.(

Written by Perplexity from public sources.